Precision medicine pioneer to establish new clinical lab in Arizona, bringing predictive testing for renal denervation to market

精准医疗先驱将在亚利桑那州建立新的临床实验室，将肾去神经支配的预测性检测推向市场

SCOTTSDALE, Ariz.

亚利桑那州斯科茨代尔

,

，

Oct. 21, 2026

2026年10月21日

/PRNewswire/ -- Xcellerant Ventures today announced a $1 million Fund I investment in Geneticure, a precision medicine pioneer developing tests that predict patient response to hypertension treatments. The capital will accelerate Geneticure's commercial scaling and support a new clinical laboratory in Arizona, expanding the state's thriving life sciences ecosystem..

/美通社/ -- Xcellerant Ventures 今日宣布，向精准医疗先驱Geneticure投资100万美元，作为其第一支基金的投资项目。Geneticure致力于开发预测高血压治疗患者反应性的检测产品。这笔资金将加速Geneticure的商业化规模扩张，并支持其在亚利桑那州新建一家临床实验室，从而进一步壮大该州蓬勃发展的生命科学生态系统。

Geneticure utilizes a non-invasive cheek swab test to analyze four physiologic pathways, predicting whether a patient with resistant hypertension will respond to renal denervation (RDN)—an FDA-approved procedure with 35 million eligible U.S. patients. Because more than 10 million of those patients may see no benefit, Geneticure's responder score gives physicians confidence in patient selection, lowers payer costs, and drives clinical adoption..

Geneticure 采用无创性口腔拭子检测，分析四条生理通路，预测难治性高血压患者对肾去神经支配术（RDN）的反应情况。RDN 是一项已获美国食品药品监督管理局（FDA）批准的手术，美国约有 3,500 万符合适应症的患者。由于其中超过 1,000 万患者可能无法从中获益，Geneticure 的反应者评分有助于增强医生在患者选择方面的信心，降低支付方成本，并推动临床应用的普及。

'Renal denervation is a game-changer, but identifying the right candidates has been the critical missing link,' said Mike Shufeldt, General Partner at Xcellerant Ventures. 'Geneticure delivers that clarity. We are thrilled to back a team with deep Arizona roots as they build a state-of-the-art laboratory here, bringing healthtech innovation and biotech jobs to our local economy.'.

“肾去神经支配技术是一项颠覆性突破，但识别合适的候选患者一直是关键缺失环节。”Xcellerant Ventures 的普通合伙人迈克·舒费尔特表示，“Geneticure 提供了这种清晰度。我们很高兴支持一个在亚利桑那州根基深厚的团队，他们在此建立一座尖端实验室，为当地经济带来健康科技创新和生物技术就业岗位。”

'Increasing our presence in Arizona puts Geneticure close to the clinical partners and talent we need to scale,' said Scott Snyder, CEO of Geneticure. 'Xcellerant brings more than capital, and we are excited to work with their team as we bring renal denervation responder testing to physicians and patients.'.

“增加我们在亚利桑那州的布局，使 Geneticure 更贴近我们实现规模化发展所需的临床合作伙伴和人才。”Geneticure 首席执行官 Scott Snyder 表示。“Xcellerant 带来的不仅仅是资本，我们很高兴与其团队携手合作，共同向医生和患者提供肾去神经支配反应者检测服务。”

Geneticure will use the funding to advance clinical validation, refine its reimbursement strategy, and build commercial readiness ahead of a planned Series A round. Alongside its RDN platform, Geneticure holds four U.S. patents and offers a commercial hypertension test guiding daily medication selection..

Geneticure将利用这笔资金推进临床验证，完善其报销策略，并在计划的A轮融资前做好商业化准备。除了其RDN平台外，Geneticure还拥有四项美国专利，并提供一项商业性高血压检测服务，用于指导日常药物选择。

While Xcellerant's institutional Fund I is now closed, individual investors can access Xcellerant's early-stage healthcare pipeline through Jetstream Venture Fund (

尽管 Xcellerant 的机构基金 Fund I 现已关闭，但个人投资者仍可通过 Jetstream 风险投资基金参与 Xcellerant 的早期医疗保健项目管道（

jvf.vc

jvf.vc

), a first-of-its-kind, retail-accessible venture fund designed to democratize VC investing.

），这是一只首创的、面向零售投资者开放的 venture fund，旨在使风险投资大众化。

About Geneticure

关于 Geneticure

Geneticure is a precision medicine company with operations in Arizona and Minnesota. Its patented genetic tests help physicians predict patient response to hypertension treatments, including medication selection and renal denervation. geneticure.com.

Geneticure 是一家精准医疗公司，在亚利桑那州和明尼苏达州开展业务。其拥有专利的基因检测有助于医生预测患者对高血压治疗的反应，包括药物选择和肾去神经支配术。网址：geneticure.com。

About Xcellerant Ventures

关于 Xcellerant Ventures

Xcellerant Ventures is a Scottsdale, Arizona-based venture capital firm investing in early-stage healthcare technology companies that improve clinical outcomes and reduce costs. xcellerantventures.com.

Xcellerant Ventures 是一家总部位于亚利桑那州斯科茨代尔的风险投资公司，专注于投资能够改善临床疗效并降低成本的早期医疗保健技术企业。xcellerantventures.com。

Media Contact: Dawson Fearnow,

媒体联系人：Dawson Fearnow，

[email protected]

[email protected]

, 602-264-2655

，602-264-2655

SOURCE Xcellerant Ventures

来源：Xcellerant Ventures

21

二十一

%

百分比

more press release views with

更多新闻稿浏览量，借助

Request a Demo

申请演示